Outcomes following antimalarial withdrawal in patients with quiescent systemic lupus erythematosus

• Published in: Seminars in arthritis and rheumatism 2022-08, Vol.55, p.152046-152046, Article 152046
• Main Authors: Papachristos, Danaë A., Gladman, Dafna D., Su, Jiandong, Urowitz, Murray B.
• Format: Article
• Language: English
• Subjects: Disease flare; Drug taper; Hydroxychloroquine therapy withdrawal; Systemic lupus erythematosus
• ISSN: 0049-0172; 1532-866X
• DOI: 10.1016/j.semarthrit.2022.152046

Antimalarial medications (AMs) are central to the management of SLE. We investigated the rate of flare in lupus patients who withdrew AM after achieving clinical remission for at least one year, compared to those who continued therapy and compared flare rates in cases who tapered AM versus abruptly withdrew. Cases achieved clinical remission for at least one year then ceased their AM. Index date was defined as the date of complete AM cessation. Controls achieved clinical remission for at least one year and continued AM. Controls were matched according to the duration of AM before remission and the duration of therapy from remission date to case index date. All patients had ≥ 2 years of follow up. Of 1573 patients on AM, 165 achieved a one-year remission and then ceased their AM. 96 had adequate follow-up, 88 were successfully matched to one control and 85 to 2 controls for a total of 173 controls. Flare occurred in 61.4% of cases and 45.1% of controls (p = 0.002). 52.3% patients who withdrew AM later restarted it due to disease flare. 88% recaptured control or improved, while 12% did not. Patients who tapered had significantly fewer flares (45.9% vs. 72.6%; p = 0.01). AMs aid in preventing disease flare even in patients who have achieved prolonged clinical remission. Tapering AM results in lower flare rates. Hence, except in the setting of toxicity, cessation of antimalarial therapy in patients with prolonged disease quiescence is feasible using a slow taper.